– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was ...
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback